{"id":"NCT02992925","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Phase 3 Study of BK1310 in Healthy Infants","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2017-12","completion":"2018-11","firstPosted":"2016-12-14","resultsPosted":"2025-01-07","lastUpdate":"2025-01-07"},"enrollment":370,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Immunization; Infection"],"interventions":[{"type":"BIOLOGICAL","name":"DPT-IPV-Hib-High（Combined Vaccine）","otherNames":["BK1310-High"]},{"type":"BIOLOGICAL","name":"DPT-IPV-Hib-Low（Combined Vaccine）","otherNames":["BK1310-Low"]},{"type":"BIOLOGICAL","name":"Hib vaccine","otherNames":["ActHIB®"]},{"type":"BIOLOGICAL","name":"DPT-IPV","otherNames":["Tetrabik"]}],"arms":[{"label":"Cohort 1: BK1310-High","type":"EXPERIMENTAL"},{"label":"Cohort 1: BK1310-Low","type":"EXPERIMENTAL"},{"label":"Cohort 2: BK1310-High or -Low","type":"EXPERIMENTAL"},{"label":"Cohort 2: ActHIB® and Tetrabik","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to:\n\n* (cohort 1) evaluate safety and immunogenicity (Haemophilus influenzae type b, Hib) of BK1310.\n* (cohort 2) evaluate efficacy and safety of BK1310 using ActHIB® and Tetrabik as a control in healthy infants.","primaryOutcome":{"measure":"Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Anti-PRP","timeFrame":"4 weeks after the primary immunization (Visit 4)","effectByArm":[{"arm":"BK1310-High","deltaMin":100,"sd":null},{"arm":"BK1310-Low","deltaMin":100,"sd":null},{"arm":"BK1310","deltaMin":100,"sd":null},{"arm":"ActHIB® and Tetrabik (Control)","deltaMin":93.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":15},"commonTop":["Injection site erythema","Pyrexia","Injection site induration","Injection site swelling","Hypersomnia"]}}